Last reviewed · How we verify
NCT05638919: myRECOVER
Real World COVID-19 Antiviral Effectiveness Research
trial testing Oral Antiviral in COVID-19 in 660 participants. Status unknown.
30 July 2023
Quick facts
| Lead sponsor | Clinical Research Centre, Malaysia |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 660 |
| Start date | 6 December 2022 |
| Primary completion | 30 July 2023 |
| Estimated completion | 31 July 2023 |
| Sites | 8 locations across Malaysia |
Drugs / interventions tested
- Oral Antiviral — full drug profile →
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Clinical Research Centre, Malaysia
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective observational cohort study to evaluate the benefit of oral antivirals (nirmatrelvir plus ritonavir or molnupiravir) in Ministry of Health institutions. In this study, we will observe the progress of COVID-19 study participants seen in the health clinic up to 90 days from their initial visit to the health clinic.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05638919
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Clinical Research Centre, Malaysia trials
Trials by the same sponsor.
- NCT06293508 — mHealth Behavioural Intervention to Increase Breast Cancer Screening Rates Among Members of the Public · NA · terminated
- NCT05106231 — Effectiveness of PICC Improving HBA1C and Knowledge in Diabetes Mellitus Education · NA · completed
- NCT05895721 — Virtual Reality for Generalized Anxiety Disorders · NA · unknown
- NCT06163976 — Prognostic Modelling for Prediction of Mortality and Functional Disability in Critically-ill Elderly Patients · unknown
- NCT06128096 — The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD) · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05638919 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinical Research Centre, Malaysia
- Last refreshed: 23 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05638919.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing